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B I O LO GY

Going for the Trunk
BY NICHOLAS NORWITZ ’18

Summary
Although angiogenesis (new blood vessel
formation) is an absolute requirement for tumor
growth, therapies designed to treat cancer
by targeting specific angiogenic factors have
had limited success. One theory is that there
are many different angiogenic factors that
can compensate for the loss of a single factor.
Therefore, a more effective strategy may be to
move upstream, identify a factor that regulates
the expression of many different downstream
angiogenic mediators, and then measure the
effect of blocking this single common factor on
angiogenesis-mediated tumor growth.

What is Angiogenesis?
In 1971, Dr. Judah Folkman observed
that, without new blood vessel formation,
tumors arrest at a threshold size of 2-3mm
(Folkman, 1971; Hanahan and Weinberg, 2000).
Folkman also discovered that tumors release an
angiogenic promoting paracrine factor, which
he called tumor-angiogenesis factor (TAF), and
hypothesized that blocking TAF signaling might
serve as an effective cancer therapy (Folkman,
1971).
As angiogenesis is regulated by a balance
between pro-and anti-angiogenic molecules,
the basis of Folkman’s hypothesis was sound.
Therapies that shift the balance away from proangiogenic signals will impair tumor growth.
However, the problem is more complicated.
Scientists have discovered an abundance of
pro-angiogenic factors, including vascular
endothelial growth factor (VEGF), epidermal
growth factors (EGFs), transforming growth
factors (TGFs), tumor necrosis factor (TNF),
fibroblast growth factors (FGFs), platelet-derived
growth factor (PDGF), hepatocyte growth factor
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(HGF), angiopoietins, and various chemokines
(Ferrara, 2002; Bouis et al., 2006).
While different tumors promote angiogenesis
by relying on different combinations of these
factors, it is possible to develop therapies that
effectively block angiogenesis by targeting
specific angiogenic molecules (Fernando et al.,
2008; Casanovas et al., 2005; Kopetz et al., 2010).
The most studied angiogenic factor is VEGF.
Many different approaches have been developed
to target VEGF signaling including monoclonal
antibodies and receptor blockers. While many
of these therapies are initially effective, tumors
are soon able to compensate by up-regulating
other pro-angiogenic factors and overcoming
this angiogenic blockade (Casanovas et al., 2005;
Kopetz et al., 2010).

Modern Attempts to Inhibit
Angiogenesis
Modern medicine has been trying to kill
the cancer tree by chopping at the ends of its
thinnest branches, and this strategy has had
only limited success. The cancer simply learns
to rely on other branches in order to grow.
The work of Dr. Anil Sood et al. published in
Nature in February 2016, concentrates on a new
approach that is fundamentally different from
previous therapies in that it emphasizes choking
the cancer tree by chopping closer to the trunk.
By identifying and targeting the molecular fork
from which many angiogenic signals diverge,
we might be able to develop anti-angiogenic
therapies that will more successfully treat
cancer.
The most obvious approach would be to
inhibit transcription factors that up-regulate
multiple downstream angiogenic factors. Sood’s
proposed therapy essentially does just this,
but in a clever way that takes advantage of an

Figure 1: A novel antiangiogenic therapy aims
to target the trunk, not the
branches, of this metaphorical
tree of angiogenic mediators.
Source: Drawing by N. Norwitz

“While different
tumors promote
angiogenesis by
relying on different
combinations of
these factors, it is
possible to develop
therapies that
effectively block
angiogenesis by
targeting specific
angiogenic
molecules.”
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Figure 2: microRNAs (miRs)
are endogenously expressed
noncoding RNAs that knock
down the expression of target
messenger RNAs (mRNAs) by
silencing them before they can
be translated.
Source: Wikimedia Commons
(Credit: Narayanese)

Figure 3: Nanoparticles
made out of amphipathic
phospholipds allow the
delivery of exogenous miRs
into tumor tissue.
Source: Wikimedia Commons
(Credit: Jesse)
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endogenous control mechanism to amplify the
breadth of its effect. In humans, microRNAs
(miRNAs) are potent negative regulators of a
wide array of genes. miRNAs work by binding to
the 3’ untranslated regions (3’UTRs) of specific
mature RNA transcripts in order to prevent
their translation to proteins.
By correlating the expression patterns of
many miRNAs with the degree of vascularization
in tumor samples, Sood’s team was able to
identify several miRNAs that were potential
candidates for therapy. One such candidate was
miR-192. The expression of miR-192 was found
to correlate negatively with the expression of
pro-angiogenic factors and angiogenesis, and
correlate positively with patient survival.
The next goal was to discover how exactly
miR-192 blocks angiogenesis. Dr. Sood and
his colleagues identified 13 potential proangiogenic transcription factor targets of miR192. When they measured how the levels of
these transcription factors changed in cells
transfected with miR-192, two transcription
factors stood out--EGR1 and HOXB9.
To demonstrate that miR-192 impairs
angiogenesis and tumor growth in vivo by
blocking the translation of EGR1 and HOXB9,
the research team devised a single elegant
experiment. They transfected human ovarian
cancer cells with miR-192 (or a control
miRNA) before injecting the cells into mice.
By monitoring tumor size, neovascularization,
and circulating levels of EGR1 and HOXB9
as well as those angiogenic paracrine factors
downstream of EGR1 and HOXB9, the team
was able to show that miR-192 impaired tumor
growth and angiogenesis, and that miR-192
overexpression decreased the expression of
EGR1 and HOXB9. Superimposed on this
experiment were additional studies in which
miR-192 was transfected into cancer cells along
with copies of the EGR1 and HOXB9 gene that
lacked normal 3’UTRs. This rendered the EGR1
and HOXB9 transcripts effectively immune to
miR-192 and prevented miR-192 from impairing
tumor growth or angiogenesis, demonstrating
that EGR1 and HOXB9 are both necessary and
sufficient to account for the anti-angiogenic
effect of miR-192.
The highpoint of this landmark publication
was to show that exogenous treatment with miR192 could serve as a viable and effective therapy
in a murine model of ovarian cancer. The team
found that injecting nanoliposomes (DOPC)
filled with miR-192 into mice recapitulated
the anti-angiogenic effect and blocked tumor
development by over 90% (p<0.0001), without
any observable toxic side-effects. What’s more,
when DOPC miR-192 therapy was compared
to treatment with an antibody against VEGF,
the most studied angiogenic factor and most
DARTMOUTH UNDERGRADUATE JOURNAL OF SCIENCE

Figure 4: Certain tumors rely
more on angiogenesis than
others. Ovarian and kidney
tumors rely heavily on the
development of new blood
vessels and were studied in
this paper.
Source: Wikimedia Commons
(Credit: James Heilman, MD)

common modern target of anti-angiogenic
therapies, the DOPC treatment proved far more
effective at inhibiting tumor growth over the
course of three weeks (p<0.0001) (Hanahan and
Weinberg, 2000; Casanovas et al., 2005; Kopetz
et al., 2010).

unknowns, the work performed by Dr. Sood and
his team suggests that we shift our focus from
chopping at branches and try chopping at the
trunk. D
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Conclusion
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Although the future of miR-192 therapy
appears promising, certain critical questions
remain. First, it remains to be determined
whether or not tumors can adapt to miR-192
therapy as they do to other anti-angiogenic
therapies. Since miR-192 blocks at least two
transcription factors that each block substantial
and distinct arrays of angiogenic factors, it is
possible that miR-192 treatment might be the
first anti-angiogenic therapy that tumors cannot
effectively circumnavigate. Second, there is some
indication that miR-192 treatment may serve a
more complex role in preventing tumorigenesis.
miR-192 is a positive regulator of the tumor
suppressor protein p53, and loss-of-function
mutations in this gene are known to occur
in more than half of all cancers (Moore et al.,
2015; Lodish, 2000). Therefore, miR-192 therapy
could in theory increase the robustness of the
p53 DNA damage response, which may affect
tumor development and growth. Moreover, p53
is a positive regulator of the potent endogenous
anti-angiogenic Thrombospondin-1, adding yet
another layer of complexity to the potential
anti-angiogenic benefits of miR-192 treatment.
miRNA cancer therapy represents an
innovative and exciting new approach for
preventing angiogenesis and tumor growth
and/or metastasis. Whatever the caveats and the
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“It remains to
be determined
whether or not
tumors can adapt
to miR-192 therapy
as they do to other
anti-angiogenic
therapies.”
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